Neurogene Inc. heads into the week after its August 12 earnings release with analyst targets scattered across a wide range and short interest entrenched near a fifth of the free float.
The analyst reaction to earnings landed within hours of the results. Canaccord Genuity's Whitney Ijem kept her Buy rating but trimmed the target from $180 to $166. Guggenheim moved the other way, raising its target from $69 to $81 while maintaining Buy. HC Wainwright also held Buy but nudged its target down from $70 to $65. The resulting consensus mean of roughly $80 sits more than double the current price of $35.80 — a spread that reflects genuine disagreement rather than consensus conviction. Canaccord's $166 target looks like an outlier against HC Wainwright's $65, and the distance from the current price suggests the Street is pricing in significant binary clinical risk rather than a near-term re-rating. Bulls point to NGN-401 and NGN-101's durable multi-domain improvements in trials and a cash runway through Q1 2028. Bears focus on the two-candidate pipeline concentration and the inherent cost and approval risk in genetic medicine development.
Short positioning is the other major feature of this stock. Nearly 19.4% of the free float was short as of August 11 — elevated for any name, extreme for a small-cap biotech. That level has come down from over 26% earlier in the year and has drifted roughly 14% lower over the past month, suggesting some bears have reduced exposure alongside the stock's own 10% pullback over that period. The ORTEX short score sits at 76.3, near the top of recent readings, which flags the combination of high SI, high days-to-cover (official data puts it at 16 days), and overall borrow market dynamics as a meaningful structural feature of this name. Despite the high short interest, the borrow market is not tight — availability has dropped sharply this week to around 224% but remains well within normal range, and cost to borrow is negligible at just 0.52%. There is plenty of lending supply relative to demand, which means short sellers face little mechanical pressure from the borrow market itself.
Options traders are not adding to the cautious read. The put/call ratio of 0.22 is actually slightly above its 20-day average of 0.21, but still near the lowest readings of the past year — the 52-week high PCR was 1.52. That skew toward calls suggests options participants remain oriented toward upside rather than hedging, a contrast to the elevated short positioning in the stock itself.
The institutional register is concentrated in specialist biotech funds, with Samsara BioCapital and Redmile Group together holding around 16% of shares. Casdin Capital added 125,000 shares in Q1, and Balyasny added roughly 110,000 in the same period. BlackRock reported a fresh addition of 53,000 shares as recently as July 31. Insider activity tells a more cautious story: the CFO, Christine Mikail Cvijic, has sold shares steadily through May, June, and early July — totalling around 19,200 shares net over 90 days at prices between $21 and $36. These are smaller transactions relative to the company's float and carry low significance scores, but the consistency of the selling is worth noting alongside the institutional accumulation.
The earnings history adds context. The May 2026 print sent the stock down 10.5% on day one and 11.4% over the following five days. The June 3 release — which may reflect a different event type — produced a 5.1% gain on day one and 7.2% over five days. With the next scheduled earnings event not until November 13, the near-term focus shifts to any clinical update on NGN-401 or NGN-101, which the bull and bear cases both identify as the central driver of value. The gap between the $65 low-end analyst target and the $166 high-end will narrow or widen entirely on that data.
See the live data behind this article on ORTEX.
Open NGNE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
